RESVERLOGIX CORP (RVX.CA) Stock News

Canada - TSX:RVX - CA76128M1086 - Common Stock

0.105 CAD

0 (0%)

Last: 10/21/2025, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RVX.CA Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Seeking Alpha

Resverlogix extends debenture maturity by one year (RVX:CA)

3 years ago - By: InvestmentPitch Media and Resverlogix Corp. - Mentions: OTC

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

3 years ago - By: Resverlogix Corp

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

3 years ago - By: Resverlogix Corp

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

3 years ago - By: Resverlogix Corp

Resverlogix Announces Appointment of New Chief Scientific Officer

3 years ago - By: Resverlogix Corp

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

3 years ago - By: Resverlogix Corp

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

3 years ago - By: Resverlogix Corp

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

4 years ago - By: Resverlogix Corp

Resverlogix Announces One-Year Extension of Debenture

4 years ago - By: Resverlogix Corp

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

4 years ago - By: The Market Herald - Mentions: BABY.CA

The Power Play by The Market Herald Releases Interviews With Else Nutrition, Ayurcann Holdings, and Resverlogix

4 years ago - By: Resverlogix Corp

Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

4 years ago - By: Resverlogix Corp

Resverlogix 宣佈在加拿大開發具有前景的 2019 冠狀病毒病治療的第 2b 期測試開始患者招募和給藥

4 years ago - By: Resverlogix Corp

Resverlogix宣布在加拿大开发的一种有前景的新冠肺炎药物的2b期临床试验中开始患者招募和给药

4 years ago - By: Resverlogix Corp

Resverlogix annonce le début du recrutement et du dosage des patients pour un essai de phase 2b d’un traitement prometteur contre la COVID-19 développé au Canada

4 years ago - By: Resverlogix Corp

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

4 years ago - By: Resverlogix Corp

Resverlogix Announces Corporate Update Webcast and Conference Call

4 years ago - By: Resverlogix Corp

Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients

4 years ago - By: Resverlogix Corp

Resverlogix与阿拉伯-非洲经济最高委员会签订合作协议，以支持为新冠肺炎患者开发Apabetalone

4 years ago - By: Resverlogix Corp

Resverlogix 與阿拉伯非洲經濟最高委員會達成合作協議，以支援為 2019 冠狀病毒病患者開發 Apabetalone

4 years ago - By: Resverlogix Corp

Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone

4 years ago - By: Resverlogix Corp

Resverlogix to Participate in Leading Scientific Conferences

4 years ago - By: Resverlogix Corp

Resverlogix to Present at Upcoming Conferences

4 years ago - By: Resverlogix Corp

Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial